Cytori Therapeutics Demonstrates Human Adipose-Derived Adult Stem Cells Have the Potential to Differentiate into Spinal Disc
Cytori Therapeutics, Inc. announced research results illustrating that human adipose-derived adult stem cells can differentiate into cells displaying the phenotype of nucleus pulposus (NP) cells. The nucleus pulposus, which forms the soft gel-like center of an intervertebral disc, is adversely affected in degenerative disc disease.
"Our research demonstrates the potential for using human adipose-derived stem cells in treating patients with degenerative disc disease," stated Christopher J. Calhoun, Chief Executive Officer for Cytori Therapeutics. "We are encouraged by these early findings and have initiated preclinical animal studies to further evaluate the effect of these cells, in vivo, on injured discs."
Scientists from the Skeletal Tissue Engineering Group Amsterdam (STEGA) and Cytori Therapeutics demonstrated that an NP-phenotype was observed when adipose stem cells were grown in conditions that can be adapted to clinical practice. The human adipose stem cells and NP cells were co-cultured for 14 days. RNA expression analysis found the presence of genes which are markers of mature NP cells. One of the genes in particular forms a protein that is critical to the function of the nucleus pulposus.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.